Salute e Benessere

CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and…

Press releaseCROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)DIJON, France – September 22, 2025 (7.30 AM CET) – CROSSJECT(ISIN: FR0011716265; Euronext: ALCJ), the global specialty pharma company developing needle-free auto-injectors for emergency situations, today confirms an additional $11.3 million in funding awarded by the U.S. Biomedical Advanced Research and Development Authority (BARDA)...
Nasdaq GlobeNewswire
22/09/2025

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated…

IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacyData showed a rapid onset of action, peak effect superior to placebo, and a substantial majority of patients experiencing clinically significant longer duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity at Week 24Data to be presented...
Nasdaq GlobeNewswire
22/09/2025

VeSync Unveils Full Wellness Ecosystem at GITEX 2025: Levoit, Cosori, and…

VeSync's participation directly responds to the UAE's declaration of indoor air pollution as the nation's #2 environmental health threat. With residents spending 90% of time indoors due to extreme heat, VeSync's ecosystem delivers on its mission: "Unlock everyday wellness through integrative smart solutions that remove health barriers, deliver actionable insights, and transform daily habits." VeSync's participation directly responds to the UAE's declaration of indoor air pollution as…
PR Newswire
22/09/2025

Climate-resilient food innovation: International consortium aims to produce food…

Since 2023, a consortium consisting of research institutions and private companies has been working with a radically new approach to food production that makes it possible to replace sugar in fermentation processes with CO₂-derived acetate. Since 2023, aconsortiumconsisting of research institutions and private companies has been working with a radically new approach to food production that makes it possible to replace sugar in fermentation processes with CO₂-derived acetate. The goal is...
PR Newswire
22/09/2025

Positive phase III results show Roche’s giredestrant significantly improved…

evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1 -mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The all-oral combination was well tolerated and adverse events were consistent with the known safety profiles of the individual study treatments; no new safety signals were observedevERA is the first positive head-to-head phase III trial investigating an all-oral...
Nasdaq GlobeNewswire
22/09/2025

Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China

Allschwil, Switzerland – September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launchedQUVIVIQ ®(daridorexant)in China. QUVIVIQ, Idorsia’s dual orexin receptor antagonist, is indicated for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep. Notably, QUVIVIQ has been approved without psychotropic drug control labeling, underscoring its differentiated...
Nasdaq GlobeNewswire
22/09/2025

Press Release: Update on the US regulatory review of tolebrutinib in…

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosisParis, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and brain-penetrant investigational Bruton's tyrosine kinase (BTK) inhibitor to treat non-relapsing, secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation...
Nasdaq GlobeNewswire
22/09/2025

Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous…

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the EUParis and Tarrytown, September 22, 2025.The European Medicines Agency’s Committee for Medicinal Products for Human...
Nasdaq GlobeNewswire
22/09/2025

in-cosmetics Asia 2025: Global ingredients and innovations for Japanese beauty…

Sarah Gibson, Event Director of in-cosmetics Asia, said: "Japanese consumers expect nothing less than perfection, but the market is becoming much more complex with demographic shifts and fierce competition from international players such as South Korea, China, India, Indonesia and the US. Sarah Gibson, Event Director of in-cosmeticsAsia, said: "Japanese consumers expect nothing less than perfection, but the market is becoming much more complex with demographic shifts and fierce...
PR Newswire
22/09/2025

SiBionics' CGM Meets iCGM Special Control Criteria, Spotlighting Diabetes…

On the exhibition floor, SiBionics' next-generation devices — the GS3 Continuous Glucose Monitoring (CGM) system and the KS3 Continuous Ketone Monitoring (CKM) device — became focal points, drawing considerable attention from attendees. Visitors expressed strong interest in the products' technical strengths and clinical relevance, engaging in active dialogue with the SiBionics team about their advantages in real-world diabetes management. On the exhibition floor, SiBionics' next-generation...
PR Newswire
21/09/2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported…

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ®(deutetrabenazine) extended-release tabletsPatients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatmentAlmost all (>96%) patients relayed that AUSTEDO XR was easy to takePARSIPPANY, N.J.and TEL AVIV, Israel, Sept.20, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S...
Nasdaq GlobeNewswire
21/09/2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the…

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations 1 Additional new data comparing initiation of UZEDY ®(risperidone) versus Invega Sustenna ®(paliperidone palmitate) in hospitalized patientsfound that UZEDY was associated with shorter length of stay and was...
Nasdaq GlobeNewswire
21/09/2025

GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder).GENFIT’s decision follows the occurrence of a peritonitis...
Nasdaq GlobeNewswire
19/09/2025

Proya Cosmetics Wins IFSCC 2025 Top 10 Papers of Basic Research Award

"This award is a significant recognition of our collaborative research with Zhejiang University and highlights the transformative potential of AI in the discovery of anti-aging bioactives," said Dr. Wei. "By leveraging deep learning, we developed a high-throughput screening platform that predicts and validates the efficacy of natural products, dramatically improving R&D efficiency and precision. I am grateful to my team and partners for their dedication and support."…
PR Newswire
19/09/2025

Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based…

The company expects to list on NASDAQ in Q2 2026 According to the agreement’s terms, Kensana will not be obligated to draw down the full $120 million but can do so in part or in whole at its discretion. Kensana can also set a threshold price as the lowest price at which Kensana may issue shares to GEM under a given drawdown. Kensana will control both the timing and amount of all drawdowns and will issue common shares to GEM on each drawn down from the facility. GEM shall pay 90% of the...
Nasdaq GlobeNewswire
19/09/2025

Sleep Aids Market to Hit US$ 118.97 Billion by 2033, Growing at 7.8% CAGR -…

North America currently leads the market due to its robust healthcare infrastructure and high adoption of innovative solutions. The Asia-Pacific region is emerging as the fastest-growing region, driven by urbanization, rising stress levels, and increasing disposable incomes. With continuous product innovations, supportive government health initiatives, and a growing emphasis on mental health and overall well-being, the Sleep Aids market is poised for sustained expansion, positioning itself as a…
PR Newswire
19/09/2025

Sironax Named to 2025 Endpoints 11 List of the Most Promising Biotech Startups

“We are thrilled to have received this distinguished recognition from Endpoint News as a reflection of our scientific innovation to date,” said Dr. Shefali Agarwal, President and CEO of Sironax. “Our extensive research capabilities have enabled us to develop a robust clinical pipeline with potential application across numerous conditions. To advance our clinical programs, we recently expanded our global presence into additional key markets, highlighted by our new administrative headquarters...
Nasdaq GlobeNewswire
19/09/2025

Smart Medical Devices Market Size to Reach $180.4 Billion by 2033 - Strategic…

Download FREE Exclusive Sample Report: https://www.datamintelligence.com/download-sample/smart-medical-devices-market Download FREE Exclusive Sample Report:https://www.datamintelligence.com/download-sample/smart-medical-devices-market Browse in-depth TOC on 'Smart Medical Devices Market' 62 – Tables 56 – Figures 159 – Pages Market Drivers and Corporate Implications Chronic Disease Burden Cardiovascular diseases, diabetes, cancer, and respiratory illnesses account for...
PR Newswire
19/09/2025

In Vitro Diagnostics (IVD) Quality Control Market worth $2.15 billion by 2030…

Browse in-depth TOC on 'IVD Quality Control Market' Browse in-depth TOC on 'IVD Quality Control Market' 422 - Tables 55 - Figures 378 - Pages Based on product & service, the IVD quality control market is segmented into quality control products, data management solutions, and quality assurance services. Among these, the quality control products segment is projected to register the highest growth rate during the forecast period. This growth is primarily driven by the growing...
PR Newswire
19/09/2025

Veterinary Monoclonal Antibodies Market worth $3.06 billion by 2030 with 12.4%…

Browse in-depth TOC on "Veterinary Monoclonal Antibodies Market" Browse in-depth TOC on "Veterinary Monoclonal Antibodies Market" 230 - Tables 54 - Figures 253 - Pages By route of administration, the subcutaneous segment accounted for the highest share in the veterinary monoclonal antibodies market, largely due to their ease of administration and improved compliance in animals. The subcutaneous route provides sustained drug release in the body and reduces the risk of...
PR Newswire
19/09/2025

Liver Cancer Therapeutics Market Size Surpasses USD 13.16 Billion by 2032…

A significant advancement in liver cancer therapeutics is the approval of combination immunotherapy regimens. Notably, AstraZeneca's Imfinzi (durvalumab) plus Imjudo (tremelimumab) gained global recognition after the HIMALAYA trial demonstrated a meaningful overall survival benefit in patients with unresectable hepatocellular carcinoma. This approval provided a new first-line treatment option beyond tyrosine kinase inhibitors and VEGF-targeted therapies, offering durable survival outcomes for a…
PR Newswire
19/09/2025

Charity for Civil Servants joins as sponsor for Pearn Kandola's Psychological…

"Charity for Civil Servants' mission to help current, former and retired civil servants overcome life's challenges and thrive aligns with our own mission of making the world fairer. We are delighted to have their support as sponsors for Psychological Safety Week, and we are proud to continue this partnership by facilitating a session for their Mental Health and Wellbeing Conference in October this year." "Charity for Civil Servants' mission to help current, former and retired…
PR Newswire
19/09/2025

Change to Essity's Executive Management Team

"Donato Giorgio has been a strong force behind Essity's transformation in global supply chain excellence. I would like to thank Donato for his contributions to Global Supply Chain and to Essity and wish him all the best in his future endeavors," says Ulrika Kolsrud, President and CEO, Essity. " Donato Giorgiohas been a strong force behind Essity's transformation in global supply chain excellence. I would like to thank Donato for his contributions to Global Supply Chain and to…
PR Newswire
19/09/2025

CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for…

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years 1 Subcutaneous Lunsumio has potential to substantially reduce treatment administration time with an approximately one minute injection, compared with 2-4 hours IV infusionIf approved, Lunsumio would be the first treatment available for people with follicular lymphoma after two or more lines of systemic therapy, which is both...
Nasdaq GlobeNewswire
19/09/2025
Altri  Comunicati